MARC Record from marc_columbia

LEADER: 06331cam a22004814a 4500
001 6608763
005 20221122041854.0
008 071116t20082008dcua b 001 0 eng
010 $a 2007047397
015 $aGBA823601$2bnb
016 7 $a101321136$2DNLM
016 7 $a014531827$2Uk
020 $a9781555814083
020 $a1555814085
029 1 $aNLM$b101321136
029 1 $aIG#$b9781555814083
035 $a(OCoLC)ocn181862805
035 $a(OCoLC)181862805
035 $a(NNC)6608763
035 $a6608763
040 $aDNLM/DLC$cDLC$dNLM$dUKM$dBAKER$dBTCTA$dYDXCP$dIG#$dC#P$dOrLoB-B
042 $apcc
050 00 $aQR189.5.P58$bP54 2008
060 10 $aWC 217$bP7375 2008
082 00 $a615/.372$222
245 00 $aPneumococcal vaccines :$bthe impact of conjugate vaccine /$cedited by George R. Siber, Keith P. Klugman, P. Helena Mäkelä.
260 $aWashington, DC :$bASM Press,$c[2008], ©2008.
300 $axix, 449 pages :$billustrations ;$c29 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $tDedication: Robert Austrian /$rJeffrey N. Weiser -- $gI.$tHistory -- $g1.$tThe History of Pneumococcal Disease /$rBarry M. Gray and Daniel M. Musher -- $g2.$tHistory of Pneumococcal Immunization /$rP. Helena Makela and Jay C. Butler -- $gII.$tBiological Basis -- $g3.$tGenetics, Biosynthesis, and Chemistry of Pneumococcal Capsular Polysaccharides /$rJanet Yother, Stephen D. Bentley and John P. Hennessey, Jr. -- $g4.$tAnimal Models of Invasive Pneumococcal Disease /$rDavid E. Briles, Susan K. Hollingshead and Ingileif Jonsdottir -- $g5.$tAnimal Models of Pneumococcal Colonization /$rRichard Malley and Jeffrey N. Weiser -- $g6.$tThe Immunobiology of Polysaccharide and Conjugate Vaccines /$rDavid Goldblatt, Tracy Assari and Clifford Snapper -- $g7.$tInteractions of Streptococcus pneumoniae with Complement Proteins /$rMargaret K. Hostetter -- $gIII.$tClinical Disease and Epidemiology -- $g8.$tEpidemiology, Diagnosis, and Treatment of Serious Pneumococcal Infections in Children /$rShabir A. Madhi and Stephen I. Pelton -- $g9.$tPneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and Therapy /$rJeffrey B. Rubins, David R. Boulware and Edward N. Janoff -- $g10.$tPneumococcal Serotype Epidemiology /$rWilliam P. Hausdorff, Angela B. Brueggemann, Jill G. Hackell and J. Anthony G. Scott -- $gIV.$tManufacturing and Product Release Issues -- $g11.$tConjugation Chemistry /$rAndrew Lees, Velupillai Puvanesarajah and Carl E. Frasch -- $g12.$tPneumococcal Vaccines: Manufacture and Quality Control for Product Release /$rMilan S. Blake -- $g13.$tLicensing of Pneumococcal Conjugate Vaccines for Children and Adults: Regulatory Perspective from the European Medicines Agency and the U.S. Food and Drug Administration /$rMarion F. Gruber, Douglas Pratt and Manfred Haase -- $gV.$tImmunogenicity -- $g14.$tQuantitation of Anti-Pneumococcal Capsular Antibody in Ligand-Binding Assays /$rDace V. Madore, Sally A. Quataert and Merja Vakevainen -- $g15.$tFunctional Assays for Pneumococcal Antibody /$rMoon H. Nahm and Sandra Romero-Steiner -- $g16.$tImmunogenicity and Reactogenicity of Pneumococcal Conjugate Vaccines in Infants and Children /$rHelena Kayhty, Stephen Lockhart and Lode Schuerman -- $g17.$tImmunogenicity and Safety in Adults /$rLisa A. Jackson and George R. Siber -- $g18.$tImmunogenicity in High-Risk and Immunocompromised Children and Adults /$rNeil French, Sharon Nachman and Stephen I. Pelton -- $gVI.$tEfficacy and Safety -- $g19.$tNasopharyngeal Carriage /$rKatherine L. O'brien, Ron Dagan and P. Helena Makela -- $g20.$tAcute Otitis Media and Its Sequelae /$rTerhi Kilpi and Lode Schuerman -- $g21.$tMeta-Analysis of the Efficacy of Conjugate Vaccines against Invasive Pneumococcal Disease /$rKeith P. Klugman, Felicity Cutts, Richard A. Adegbola, Steven Black, Shabir A. Madhi, Katherine L. O'brien, Mathuram Santosham, Henry Shinefield and Jonathan A. C. Sterne -- $g22.$tEfficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia /$rShabir A. Madhi and Keith P. Klugman -- $g23.$tEstablishing Immune Correlates of Protection /$rRobert C. Koihberger, Jukka Jokinen and George R. Siber -- $gVII.$tPublic Health Impact -- $g24.$tDirect and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice /$rCynthia G. Whitney and Matthew R. Moore -- $g25.$tImpact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance /$rRon Dagan and Keith P. Klugman -- $g26.$tPharmacoeconomics of Pneumococcal Conjugate Vaccines /$rAnushua Sinha and G. Thomas Ray -- $g27.$tOpportunities and Challenges for Pneumococcal Conjugate Vaccines in Low- and Middle-Income Countries /$rOrin S. Levine and Brian Greenwood -- $gVIII.$tWhere Next -- $g28.$tProtein Vaccines /$rJames C. Paton and John W. Boslego -- $tConclusions /$rGeorge R. Siber, Keith P. Klugman and P. Helena Makela.
520 1 $a"Acute respiratory infections due to pneumococci are the leading vaccine-preventable cause of death. The first pneumococcal conjugate vaccine was licensed 7 years ago in the United States and is now in general use worldwide. While the vaccine's dramatic impact on the target population was anticipated, the magnitude of herd immunity provided to unimmunized individuals was not. This benefit has enormously enhanced the public health impact of the vaccine."--BOOK JACKET.
650 0 $aPneumococcal vaccine.$0http://id.loc.gov/authorities/subjects/sh85103620
650 12 $aPneumococcal Vaccines$ximmunology.$0https://id.nlm.nih.gov/mesh/D022242Q000276
650 12 $aPneumococcal Vaccines$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D022242Q000627
650 22 $aMeta-Analysis as Topic.$0https://id.nlm.nih.gov/mesh/D015201
650 22 $aPneumonia, Pneumococcal$xepidemiology.$0https://id.nlm.nih.gov/mesh/D011018Q000453
650 22 $aPneumonia, Pneumococcal$xprevention & control.$0https://id.nlm.nih.gov/mesh/D011018Q000517
700 1 $aSiber, George R.$0http://id.loc.gov/authorities/names/n2007185184
700 1 $aKlugman, Keith P.$0http://id.loc.gov/authorities/names/n2007185185
700 1 $aMäkelä, P. Helena.$0http://id.loc.gov/authorities/names/n85224353
852 00 $boff,hsl$hQR189.5.P58$iP54 2008 Q